Januvia (sitagliptin) is a prescription drug that’s used to treat type 2 diabetes in adults. The drug comes as an oral tablet. It’s usually taken once per day. Januvia is used in adults to treat type ...

(Reuters) - Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a ...

The Market Share for DPP-IV Inhibitors and GLP-1 Analogues Will Increase by 22 Percent Through 2019, According to Findings from Decision Resources BURLINGTON, Mass., Sept. 21 /PRNewswire/ -- Decision ...

NEW YORK (Reuters) - Aggressive marketing of Merck & Co.'s new first-in-class diabetes drug Januvia has led to a strong launch, according to data compiled by ImpactRx Inc., a market research company ...

April 18 (UPI) --In comparing three classes of medication for type 2 diabetes, researchers found one class, which includes the drugs Onglyza, Janumet and Januvia, did not reduce the risk of death.

Expert Rev Endocrinol Metab. 2008;3(6):691-697. Elimination of sitagliptin occurs primarily via renal excretion (79%) and involves active tubular secretion. Sitagliptin is a substrate for human ...

As COVID-19 spread across the globe, scientists are hunting for drugs that could be repurposed as a quick way to tackle the disease. Among them is a University of Miami researcher who has pointed to ...

> The FDA's decision yesterday to require a new trial of Novartis' Galvus is seen as a big win for Merck, which is promoting its competing diabetes drug Januvia. Galvus is seen as a blockbuster drug ...

Merck’s attempt to show doctors in British Columbia are opposed to the government’s 2014 decision to pull diabetes medication Januvia off the national health formulary has kicked off a debate about ...

Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...